Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TELA Bio (TELA) Capital Expenditures (2018 - 2025)

TELA Bio (TELA) has 8 years of Capital Expenditures data on record, last reported at $331000.0 in Q3 2025.

  • For Q3 2025, Capital Expenditures rose 175.83% year-over-year to $331000.0; the TTM value through Sep 2025 reached $1.2 million, up 208.16%, while the annual FY2024 figure was $989000.0, 61.87% up from the prior year.
  • Capital Expenditures reached $331000.0 in Q3 2025 per TELA's latest filing, up from -$6000.0 in the prior quarter.
  • Across five years, Capital Expenditures topped out at $814000.0 in Q4 2024 and bottomed at -$528000.0 in Q3 2022.
  • Average Capital Expenditures over 5 years is $136368.4, with a median of $115000.0 recorded in 2023.
  • Peak YoY movement for Capital Expenditures: tumbled 1156.0% in 2022, then soared 20600.0% in 2023.
  • A 5-year view of Capital Expenditures shows it stood at $530000.0 in 2021, then crashed by 100.19% to -$1000.0 in 2022, then skyrocketed by 20600.0% to $205000.0 in 2023, then surged by 297.07% to $814000.0 in 2024, then crashed by 59.34% to $331000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Capital Expenditures were $331000.0 in Q3 2025, -$6000.0 in Q2 2025, and $32000.0 in Q1 2025.